IRC18 Antibody

What is IL-18 and why is it significant in immunological research?

IL-18 is an immunoregulatory cytokine that functions as a potent inducer of T helper 1 (Th1) and cytotoxic immune responses. Its significance lies in its central role in regulating inflammation, host defense mechanisms, and immune surveillance. IL-18 exerts its biological functions by stimulating IFN-γ production by T cells and NK cells, while also inducing CD8+ T cell and NK-mediated cytotoxicity. This makes IL-18 a crucial target for immunological research, particularly in contexts of infection, autoimmunity, and cancer immunotherapy. The balance between IL-18 and its regulatory binding protein (IL-18BP) is particularly important as their disbalance can lead to systemic inflammation and pathological conditions .

How does IL-18 signaling work, and how do antibodies interact with this pathway?

IL-18 signaling occurs through binding to its cognate receptor complex consisting of IL-18Rα and IL-18Rβ. This binding initiates a signaling cascade that leads to activation of NF-κB and subsequent production of inflammatory mediators, particularly IFN-γ. IL-18 binding protein (IL-18BP) serves as a decoy receptor, forming high-affinity complexes with IL-18 to prevent receptor binding and subsequent signaling. Anti-IL-18 antibodies can neutralize IL-18 directly, while anti-IL-18BP antibodies (like antibody clone 445) can neutralize IL-18BP, thereby enhancing IL-18 bioavailability and activity. Other antibodies (like clone 441) can bind to IL-18BP without interfering with its regulatory function, making them valuable research tools for detecting IL-18BP without altering its physiological function .

What are the main types of IL-18 antibodies available for research?

IL-18 antibodies for research purposes generally fall into three categories:

• Anti-IL-18 neutralizing antibodies: These directly bind to IL-18 and prevent its interaction with receptors

• Anti-IL-18 non-neutralizing antibodies: These bind IL-18 without affecting its function, useful for detection applications

• Anti-IL-18BP antibodies: These target the IL-18 binding protein and can be neutralizing (like antibody 445) or non-neutralizing (like antibody 441)

Each type serves different research purposes, from blocking IL-18 signaling to detecting IL-18 in various experimental systems without interfering with its biological function .

How should I design a bioassay to evaluate IL-18 antibody functionality?

When designing a bioassay to evaluate IL-18 antibody functionality, consider creating a stable cell line expressing IL-18 receptors. For example, researchers have successfully established a stably transfected RAW 264.7 cell line with constitutive expression of IL-18Rα/β. The functionality of these receptors should be validated through flow cytometry to confirm surface expression and through stimulation with recombinant IL-18 to verify downstream signaling.

A comprehensive bioassay protocol would include:

• Stimulating receptor-expressing cells with a fixed concentration of IL-18 (e.g., 5 ng/mL)

• Adding IL-18BP at concentrations that inhibit most of IL-18's stimulatory activity

• Testing antibodies at different molar ratios relative to IL-18BP

• Measuring readouts such as TNFα production to assess IL-18 signaling

Include appropriate controls such as cells transfected with an empty vector and LPS stimulation as a receptor-independent control. This approach allows for the determination of IC50 values and the characterization of antibodies as neutralizing or non-neutralizing with respect to IL-18BP function .

What considerations are important when selecting antigens for developing IL-18 antibodies?

Antigen selection is critical for developing effective IL-18 antibodies. You should consider:

• Antigen format: Choose between peptides (typically 10-25 amino acids) or full-length recombinant proteins. Peptides are generally preferred for applications like immunohistochemistry (IHC) and western blot (WB), while full-length recombinant proteins are advantageous for raising antibodies against folding-specific epitopes, which is crucial for applications requiring detection of native targets (e.g., immunoassays and flow cytometry) .

• Species cross-reactivity: Determine whether cross-reactivity between species is desired. If developing antibodies for use across multiple species, select conserved regions within the IL-18 sequence.

• Domain specificity: Consider targeting specific functional domains of IL-18 based on your research objectives, such as receptor-binding domains if developing neutralizing antibodies.

• Post-translational modifications: Account for glycosylation and other modifications that may affect epitope recognition, particularly as IL-18BP shows different degrees of glycosylation as evidenced by multiple bands in gel electrophoresis .

How can I validate the specificity of IL-18 antibodies for research applications?

Validating IL-18 antibody specificity requires a multi-faceted approach:

• ELISA testing: Develop sandwich ELISAs using the antibody as a capture antibody to confirm binding to recombinant IL-18 or IL-18BP.

• Pulldown experiments: Verify binding to native IL-18 or IL-18BP in biological samples through immunoprecipitation followed by western blotting.

• Knockout controls: Use samples from IL-18 KO or IL-18BP KO mice (or equivalent systems) as negative controls to confirm specificity.

• Binding affinity assessment: Employ techniques like biolayer interferometry (BLI) to determine binding kinetics and affinity (KD values).

• Cross-reactivity testing: Examine potential cross-reactivity with related cytokines or in different species if relevant to your research.

• Functional validation: Confirm whether the antibody interferes with IL-18 function using bioassays that measure downstream signaling events like cytokine production.

In research by Girard-Guyonvarc'h et al., antibodies 441 and 445 were validated using these approaches, revealing they had comparable IL-18BP binding affinity in the low nanomolar range despite their distinct functional effects on IL-18BP activity .

How can IL-18BP-neutralizing antibodies be used to enhance cancer immunotherapy approaches?

IL-18BP-neutralizing antibodies represent a promising strategy for enhancing cancer immunotherapy by increasing the bioavailability of active IL-18, which potentiates anti-tumor immune responses. Implementation strategies include:

• Tumor microenvironment targeting: Administration of IL-18BP-neutralizing antibodies (like antibody 445) can enhance local IL-18 activity within the tumor microenvironment, promoting IFN-γ production and cytotoxic responses against cancer cells.

• Combination with checkpoint inhibitors: IL-18BP neutralization can complement checkpoint inhibitor therapies by activating complementary immune pathways.

• Vaccine adjuvant applications: These antibodies may improve responses to cancer vaccines through enhanced Th1-type immunity.

Research has demonstrated that administration of anti-IL-18BP antibodies in mouse cancer models showed marked beneficial effects by increasing immune responses against cancer cells. Importantly, this approach appears to enhance immune activity primarily within the tumor microenvironment without significant systemic effects, suggesting a favorable safety profile compared to direct cytokine administration. The specificity of this approach is substantiated by experiments showing that antibody 445's effects were absent in IL-18BP KO and IL-18 KO mice, confirming that its activity is dependent on the IL-18/IL-18BP axis .

What role do IL-18 antibodies play in studying inflammatory and autoimmune conditions?

IL-18 antibodies serve as crucial tools for investigating inflammatory and autoimmune conditions through several research applications:

• Macrophage Activation Syndrome (MAS) models: Anti-IL-18BP antibodies like clone 445 significantly aggravate CpG-induced MAS in mice, demonstrating increased weight loss, splenomegaly, anemia, elevated IFN-γ and CXCL9 levels, and disturbed immune cell distributions. This makes them valuable tools for studying hyperinflammatory conditions.

• Cytokine storm research: By modulating IL-18 signaling, these antibodies help elucidate mechanisms underlying cytokine storm syndromes, which are relevant to conditions ranging from hemophagocytic lymphohistiocytosis to COVID-19 complications.

• Biomarker validation: Anti-IL-18 antibodies enable the development of assays to measure free versus bound IL-18, helping validate IL-18 as a biomarker for disease severity and treatment response.

• Therapeutic target identification: Studies using these antibodies help identify downstream pathways that might represent novel therapeutic targets in inflammatory diseases.

Researchers should note that while IL-18BP neutralization can exacerbate inflammatory conditions in models like CpG-induced MAS, the role of IL-18 varies by disease context, underscoring the importance of careful experimental design when using these antibodies as research tools .

How can data from IL-18 antibody studies be integrated with broader immunological findings?

Integrating IL-18 antibody research with broader immunological findings requires a multidimensional approach:

• Cytokine network analysis: Correlate IL-18 signaling with other cytokine pathways, particularly those in the IL-1 family and IFN-γ-related cascades. For example, research has shown that IL-36γ, another IL-1 family cytokine with Th1 activity, enhanced humoral responses to vaccines in adult mice but caused TNFα-dependent cytokine storms in neonates, highlighting age-dependent immune network differences.

• Immune cell phenotyping: Analyze changes in immune cell populations in response to IL-18 pathway modulation. Studies with anti-IL-18BP antibody 445 showed altered distributions of splenic macrophages, neutrophils, T cells, and NK cells compared to controls treated with antibody 441.

• Transcriptomic integration: Combine IL-18 protein-level findings with transcriptomic data by examining IFN-γ signature genes like Cxcl9 and Ciita, which were upregulated in the spleens of mice treated with anti-IL-18BP neutralizing antibodies.

• Systems biology approaches: Use computational models to predict how IL-18 pathway modulation affects broader immune networks, validating predictions through targeted experiments.

• Translational correlation: Connect findings from animal models using IL-18 antibodies to human clinical data, particularly in contexts like malignant lymphoma where IL-18 pathway activation may influence disease progression or treatment response .

How can inconsistencies in IL-18 antibody performance across different assays be resolved?

When encountering inconsistencies in IL-18 antibody performance across different assays, consider these methodological approaches:

• Epitope accessibility analysis: Determine whether the antibody recognizes linear or conformational epitopes. Antibodies raised against peptides may perform well in Western blots but poorly in applications requiring recognition of native proteins. Similarly, antibodies raised against recombinant proteins may show the opposite pattern.

• Buffer optimization: Assay-specific buffers can affect epitope exposure and antibody binding. Systematically test different buffer compositions, pH conditions, and detergent concentrations to optimize antibody performance for each application.

• Binding kinetics assessment: Use surface plasmon resonance or biolayer interferometry to compare antibody-antigen interactions under different conditions. For instance, while antibodies 441 and 445 showed similar binding affinities to IL-18BP, they exhibited drastically different functional effects.

• Pre-formed complex consideration: Test whether the antibody can recognize both free and complex-bound targets. Some antibodies may be unable to disrupt pre-formed IL-18:IL-18BP complexes while still binding to free IL-18BP.

• Cross-validation with multiple antibody clones: Use multiple antibodies targeting different epitopes of the same protein to verify results. When discrepancies occur, examine whether they correlate with epitope location or antibody isotype.

• Application-specific validation: For each application, validate using positive and negative controls, including samples from knockout models when available. This approach revealed that while antibody 445 disrupted IL-18:IL-18BP complexes, antibody 441 co-immunoprecipitated these complexes without disruption .

What factors might explain contradictory results when studying IL-18 antibodies in different disease models?

Contradictory results when studying IL-18 antibodies across different disease models may stem from several factors:

• Disease-specific cytokine milieu: The background inflammatory environment varies significantly between disease models, affecting how IL-18 pathway modulation manifests. For example, the effect of IL-18BP neutralization likely differs between cancer models (where enhancing IL-18 activity may be beneficial) versus autoimmune models (where it might exacerbate inflammation).

• Timing of intervention: The stage of disease when antibodies are administered can dramatically alter outcomes. IL-18 may play different roles during disease initiation versus established disease.

• Tissue-specific effects: IL-18 signaling varies by tissue, as evidenced by the observation that anti-IL-18BP antibodies showed effects primarily in the tumor microenvironment without significant systemic inflammation.

• Genetic background variations: Different mouse strains or genetic backgrounds can show varied responses to IL-18 pathway modulation, potentially explaining contradictory results between similar experimental approaches.

• Compensatory mechanisms: Long-term blockade of IL-18BP might trigger compensatory mechanisms absent in acute interventions or genetic knockout models.

• Antibody characteristics: Technical differences between antibodies, including isotype, affinity, and ability to disrupt preformed complexes, significantly impact experimental outcomes. For instance, while both antibodies 441 and 445 bound IL-18BP with similar affinity, only 445 could release IL-18 from preformed IL-18:IL-18BP complexes .

How should researchers interpret negative results in IL-18 antibody experiments?

When interpreting negative results in IL-18 antibody experiments, consider these analytical approaches:

• Antibody functionality verification: First confirm the antibody's basic functionality through simple binding assays. Even high-affinity antibodies may fail to produce expected biological effects if they bind non-functional epitopes.

• Assay sensitivity assessment: Determine whether your detection method is sufficiently sensitive for your experimental system. For instance, home-made ELISAs developed to detect free IL-18 revealed that antibody 445, but not 441, allowed detection of spiked IL-18 in wild-type mouse serum.

• Biological redundancy consideration: IL-18 functions may be compensated by redundant cytokine pathways. Negative results might indicate redundancy rather than antibody failure.

• Checkpoint verification: Validate intermediate steps in your experimental pipeline. For example, before concluding an anti-IL-18BP antibody lacks neutralizing capacity, verify IL-18BP protein expression and IL-18 receptor functionality in your system.

• Appropriate controls integration: Include both positive controls (known to elicit a response) and negative controls (genetic knockouts or irrelevant antibodies). The research demonstrating antibody 445's effects used IL-18BP KO and IL-18 KO mice as controls to confirm specificity.

• Context-dependent signaling consideration: IL-18 effects may depend on the presence of co-stimulatory signals. Negative results might reflect absence of necessary co-factors rather than antibody failure .

How might advanced antibody engineering improve IL-18 targeting specificity?

Advanced antibody engineering holds promise for enhancing IL-18 targeting through several innovative approaches:

• Domain-specific targeting: Engineering antibodies that recognize specific functional domains of IL-18 or IL-18BP can provide more precise pathway modulation. For example, antibodies specifically targeting the receptor-binding domain of IL-18 could offer more selective neutralization.

• Bispecific antibody development: Creating bispecific antibodies that simultaneously target IL-18 and other immune mediators could enhance therapeutic efficacy. For instance, a bispecific antibody targeting both IL-18BP and tumor-associated antigens could focus IL-18 activity specifically within the tumor microenvironment.

• Conditional activation mechanisms: Developing antibodies with activity dependent on the tissue microenvironment, such as pH-sensitive binding or protease-activated antibodies, could localize effects to disease sites.

• Fc engineering: Modifying the Fc region can enhance or eliminate effector functions. The research described murinized anti-IL-18BP antibodies as IgG2a with LALAPG mutation in the Fc region to prevent Fcγ receptor binding and complement activation, demonstrating how Fc engineering can isolate antibody binding effects from other immune functions.

• Intracellular antibody delivery: Developing methods to deliver antibodies intracellularly could target IL-18 pathway components before secretion or during processing, offering new regulatory opportunities.

These engineering approaches could significantly advance the precision of IL-18 pathway modulation, particularly important given the observation that while IL-18BP blockade shows promise in cancer models, careful preclinical data is needed to ensure such approaches don't lead to uncontrolled systemic hyperinflammation .

What emerging applications for IL-18 antibodies are being explored in hematological malignancies?

Emerging applications for IL-18 antibodies in hematological malignancies represent a frontier in immunotherapy:

• Lymphoma immunotherapy enhancement: IL-18BP neutralizing antibodies are being investigated as potential enhancers of anti-tumor immunity in malignant lymphomas. The International Conference on Malignant Lymphoma (ICML) has highlighted IL-18 pathway modulation as a promising approach, particularly in diffuse large B-cell lymphoma and chronic lymphocytic leukemia contexts .

• CAR-T cell therapy augmentation: Combining IL-18 pathway modulation with CAR-T cell therapy represents a promising direction. Reports from the ICML indicate that fourth-generation huCART19-IL18 can produce durable responses in lymphoma patients previously relapsed/refractory to conventional anti-CD19 CAR T-cell therapy .

• Richter's Syndrome targeted approaches: Targeting the IL-18 pathway may offer new treatment avenues for Richter's Syndrome, an aggressive transformation of chronic lymphocytic leukemia that currently has limited therapeutic options .

• Biomarker development: IL-18 antibodies are being employed to develop assays that can predict response to therapy or disease progression in hematological malignancies, potentially allowing for more personalized treatment approaches.

• Combination with checkpoint inhibitors: Research is examining whether IL-18 pathway activation through IL-18BP neutralization can enhance responses to checkpoint inhibitors like nivolumab in lymphoma patients, building on successful combination approaches seen in other cancers .

These applications highlight the potential for IL-18 antibodies to contribute to the evolving landscape of hematological malignancy treatment, with particular promise in enhancing existing immunotherapeutic approaches.

What are the optimal protocols for IL-18 antibody validation in tissue samples?

Optimal protocols for IL-18 antibody validation in tissue samples require rigorous, multi-step approaches:

• Initial specificity screening:

  • Western blot validation using recombinant IL-18 or IL-18BP

  • Testing across multiple tissue types, including positive and negative control tissues

  • Inclusion of competitive blocking with the immunizing antigen

  • Parallel testing in tissues from IL-18 or IL-18BP knockout animals

• Immunohistochemistry optimization:

  • Antigen retrieval method testing (heat-induced vs. enzymatic)

  • Fixation condition comparison (formalin, paraformaldehyde, frozen sections)

  • Antibody concentration titration (typically starting with 1-10 μg/mL)

  • Detection system comparison (avidin-biotin vs. polymer-based)

• Signal validation approaches:

  • RNAscope or in situ hybridization correlation with protein detection

  • Quantitative image analysis using standardized algorithms

  • Multi-color staining to establish cellular context of expression

  • Sequential staining to verify co-localization with known markers

• Reproducibility assessment:

  • Inter-observer and intra-observer scoring concordance

  • Batch-to-batch antibody comparison

  • Technical replicate consistency evaluation

  • Cross-platform validation (IHC vs. immunofluorescence)

For antibodies targeting IL-18BP specifically, validation should include assessment of whether the antibody binds free IL-18BP, IL-18:IL-18BP complexes, or both, as this distinction significantly impacts interpretation of staining patterns in tissues with active IL-18 signaling .

How should researchers design experiments to distinguish effects of different anti-IL-18BP antibody clones?

Designing experiments to distinguish effects of different anti-IL-18BP antibody clones requires careful consideration of their unique properties:

• Functional screening hierarchy:

  • Begin with binding affinity determination using biolayer interferometry or surface plasmon resonance

  • Assess capture ability using sandwich ELISA with recombinant IL-18BP

  • Evaluate neutralizing activity using cellular bioassays with IL-18-responsive cells

  • Test ability to release IL-18 from preformed IL-18:IL-18BP complexes

• Comparative in vitro assays:

  • Use stably transfected cell lines expressing IL-18 receptors (e.g., RAW 264.7 cells with IL-18Rα/β)

  • Compare antibodies at equivalent molar ratios to IL-18BP

  • Measure downstream readouts such as TNFα production

  • Calculate and compare IC50 values for neutralizing activity

• Time-course experiments:

  • Add antibodies at different time points relative to IL-18 and IL-18BP (simultaneous vs. delayed addition)

  • Assess whether antibodies can reverse established IL-18BP inhibition

  • Monitor duration of neutralizing effects

• In vivo model selection:

  • Choose disease models where IL-18 signaling plays a documented role

  • Use multiple doses to establish dose-response relationships

  • Compare multiple antibody clones at equimolar concentrations

  • Include genetic controls (IL-18BP KO and IL-18 KO mice)

The research by Girard-Guyonvarc'h et al. exemplifies this approach, showing that while antibodies 441 and 445 bound IL-18BP with similar affinity, only 445 neutralized IL-18BP function and aggravated CpG-induced macrophage activation syndrome, demonstrating how functional distinctions between similar antibodies can be systematically characterized .

What precautions should be taken when using IL-18 antibodies in primary human samples?

When using IL-18 antibodies in primary human samples, researchers should implement several precautions:

• Cross-reactivity verification:

  • Confirm species cross-reactivity experimentally, even for antibodies labeled as human-specific

  • Test antibody performance across different human tissue types

  • Verify recognition of naturally occurring IL-18 variants or isoforms

• Sample preparation considerations:

  • Standardize collection methods to minimize pre-analytical variables

  • Document processing time from collection to fixation/freezing

  • Establish consistent protocols for antigen retrieval in fixed tissues

  • Consider the impact of cryopreservation on epitope integrity

• Control implementation:

  • Include isotype controls matched to the primary antibody

  • Use blocking peptides to confirm specificity

  • Incorporate technical replicates across different batches

  • When possible, include samples with known IL-18 expression patterns

• Ethical and regulatory compliance:

  • Ensure appropriate ethical approval for human sample use

  • Maintain proper documentation of sample origin and consent

  • Consider demographic and clinical variables that might affect IL-18 expression

• Interpretation considerations:

  • Account for heterogeneity in primary samples

  • Recognize that IL-18BP levels may vary substantially between individuals

  • Consider that some antibodies may detect IL-18 in preformed complexes while others detect only free IL-18

Researchers should be particularly cognizant that antibodies validated in mouse models may require additional optimization for human samples, as evidenced by the finding that among the tested monoclonal antibodies against mouse IL-18BP, only one (clone 447) cross-reacted with human IL-18BPa .

Through careful implementation of these methodological approaches, researchers can maximize the reliability and interpretability of their IL-18 antibody studies across the spectrum from basic research to translational applications.